OncoMatch/Clinical Trials/NCT06439225
Platinum and Taxane Chemo in Met Castration Resistant Prostate Cancer Patients With Alterations in DNA Damage Response Genes
Is NCT06439225 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies multiple treatments including Docetaxel and Carboplatin for metastatic castration-resistant prostate cancer.
Treatment: Docetaxel · Carboplatin — The usual approach for most patients who are not in a study is treatment with docetaxel. This study is being done to answer the following question: Can the chance of prostate cancer growing or spreading be lowered by adding a drug to the usual approach? This study is being done to find out if this approach is better or worse than the usual approach for prostate cancer. The usual approach is defined as the care most people get for prostate cancer.
Check if I qualifyExtracted eligibility criteria
Cancer type
Prostate Cancer
Biomarker criteria
Required: ATM pathogenic mutation
Required: ATR pathogenic mutation
Required: BARD1 pathogenic mutation
Required: BRCA1 pathogenic mutation
Required: BRCA2 pathogenic mutation
Required: BRIP1 pathogenic mutation
Required: CDK12 pathogenic mutation
Required: CHEK1 pathogenic mutation
Required: CHEK2 pathogenic mutation
Required: ERCC2 pathogenic mutation
Required: FANCA pathogenic mutation
Required: FANCC pathogenic mutation
Required: FANCD2 pathogenic mutation
Required: FANCL pathogenic mutation
Required: PALB2 pathogenic mutation
Required: RAD51B pathogenic mutation
Required: RAD51C pathogenic mutation
Required: RAD51D pathogenic mutation
Required: RAD54L pathogenic mutation
Disease stage
Metastatic disease required
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: androgen receptor pathway inhibitor (abiraterone, enzalutamide, apalutamide, darolutamide)
Cannot have received: platinum chemotherapy (carboplatin, cisplatin, oxaliplatin, satraplatin)
Cannot have received: taxane (docetaxel, paclitaxel, cabazitaxel)
Exception: docetaxel for mcspc as long as it was no more than 6 cycles and at least 12 months have elapsed from their last treatment to the date of enrollment
Lab requirements
Blood counts
Kidney function
Liver function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify